ASX 200
Team Veye   April 02, 2026

3 ASX 200 Healthcare Shares to Buy

Team Veye   April 02, 2026
Get your Free Report on Top 5 ASX stocks for 2026

These updates show healthcare companies improving through new contracts clinical progress and better performance whereas focusing on growth efficiency and maintaining strong financial stability for future visibility.Β 

Pro Medicus Limited (ASX: PME)

Pro Medicus Limited (ASX: PME) on 1 April 2026 announced on market buyback up to ten percent shares until March 2027 showing confidence

On 9 March 2026 signed year renewals worth 40M with Medstar and Zwanger Pesiri increasing transaction pricing and adding cardiology

For period ending December 2025 revenue reached 124.8m profit rose margins improved cash increased company stayed debt free paying dividends

During period multiple contracts announced including July 2025 Colorado deal and others totaling over 280 million strengthening future revenue visibility.

Telix Pharmaceuticals Limited (ASX: TLX)

Telix Pharmaceuticals Limited (ASX: TLX) on 16 March 2026 resubmitted NDA to FDA for Pixclara brain imaging after providing extra data addressing earlier response concerns

The candidate targets recurrent glioma detection in adults and children with orphan and fast track status showing unmet need opportunity

On 10 March 2026, Phase three ProstACT study part one met goals confirming safety tolerability and expected side effects profile

Results showed therapy works with standard treatments and study now moves forward indicating progress toward broader clinical use potential

Ramsay Health Care Limited (ASX: RHC)

Ramsay Health Care Limited (ASX: RHC) on 26 February 2026 reported half year results showing underlying profit rising 8.1 percent mainly from stronger Australian operations and better hospital performance

During the period Australia segment improved margins patient demand increased and hospital capacity expanded while portfolio changes and planned acquisition aim to enhance future growth

Capital management tightened with lower spending guidance new hospital opened under budget and restructuring efforts reduced costs while distribution of Ramsay Sante stake planned

Profit surged due to prior impairments while outlook expects continued Australia momentum weaker UK activity and gradual improvement across Europe with controlled spending and stable dividends.Β 

(Source: Company Report)

Get your FREE ASX stock report

Discover our latest ASX share ideas and ongoing insights – so you're not guessing with your money

πŸ’¬

Get Your Free Report on Top 5 ASX Stocks on WhatsApp

Instant Access. No Credit Card Required.

Receive on WhatsApp

Checkout Our Recommendation for free - 7 days free trial

Start Free Trial
7‑day free trial

ASX Stock Research & Recommendations β€” 7‑day free trial

Independent, analyst‑driven insights.

  • Stock of the week report
  • Daily Analysis Report
  • No credit card required
General information only. Not financial advice.

Get Your FREE Report

Discover the Top ASX Stocks to Invest In 2026!

Expert Analysis of Top-Performing ASX Stocks

Market Insights and In-Depth Research

Buy, Sell, And Hold Recommendations

Almost There!

Enter your details to download the report

Success!

Preparing your download...

Latest Article


Post Image
Team Veye

Best ASX Tech Stocks to Buy

June 05, 2026
Post Image
Team Veye

Top income stocks Australia

June 05, 2026
Post Image
Team Veye

ASX gold mining stocks 2026

June 05, 2026

Disclaimer

Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.